个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Individualized prevention of proton pump inhibitor related adverse events by risk stratification

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 自然指数

作者：
Xia Bin[1,2] ; He Qiangsheng[1,2] ; Smith Fang Gao[3,4] ; Gkoutos V Georgios[4,5,6] ; Nirantharakumar Krishnarajah[6,7] ; Kuo Zi Chong[8] ; Wang Danni[1,2] ; Feng Qi[9] ; Cheung Eddie C[8,10] ; Dai Lunzhi[11] ; Huang Junjie[12] ; Yu Yuanyuan[13] ; Meng Wenbo[14] ; Qin Xiwen[15,16] ; Yuan Jinqiu[1,2,8] ;
机构： [1]Department of Epidemiology and Biostatistics, Clinical Big Data Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China. [2]Chinese Health RIsk MAnagement Collaboration (CHRIMAC), Shenzhen, Guangdong, China. [3]Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK. [4]University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. [5]Institute of Cancer andGenomic Sciences, University of Birmingham, Birmingham, UK. [6]College of Medical and Dental Sciences, Centre for Health Data Science, University of Birmingham, Edgbaston, Birmingham, UK. [7]Institute of Applied Health Research, University of Birmingham, Birmingham, UK. [8]Guangdong Provincial Key Laboratory of Gastroenterology, Center for Digestive Disease, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China. [9]Oxford Population Health, University of Oxford, Oxford, Oxfordshire, UK. [10]Division of Gastroenterology, Davis School of Medicine, University of California, Oakland, CA, USA. [11]National Clinical Research Center forGeriatrics and Department of General Practice, West ChinaHospital, Sichuan University, Chengdu, China. [12]J.C. School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, China. [13]Department of Surgery, The Chinese University of Hong Kong, Sha Tin, Hong Kong, China. [14]Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. [15]School of Population and Global Health, Faculty of Medicine, Density and Health Sciences, University of Western Australia, Perth, AU-WA, Australia. [16]Laboratory of Data Discovery for Health (D24H), Hong Kong Science Technology Park, Sha Tin, Hong Kong, China
出处：
DOI： 10.1038/s41467-024-48007-8
ISSN：

摘要：
Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts from the US, the UK, and China, we found that PPI use correlated with increased risk of 15 leading global diseases, such as ischemic heart disease, diabetes, respiratory infections, and chronic kidney disease. These associations showed dose-response relationships and consistency across different PPI types. PPI-related absolute risks increased with baseline risks, with approximately 82% of cases occurring in those at the upper 40% of the baseline predicted risk, and only 11.5% of cases occurring in individuals at the lower 50% of the baseline risk. While statistical association does not necessarily imply causation, its potential safety concerns suggest that personalized use of PPIs through risk stratification might guide appropriate decision-making for patients, clinicians, and the public.© 2024. The Author(s).

基金：
This research was supported by the Natural Science Foundation of China [grant number 82103913 (to Q.S.H.), 82003524 (to J.Q.Y.), 82003408 (to B.X.)], Guangdong Provincial Key Laboratory of Digestive Cancer Research,No. 2021B1212040006 (to J.Q.Y.), the Start-up Fund for the 100 Top Talents Program, SYSU No.392012 (to J.Q.Y.), and the Research Supporting Start-up Fund for Associate researcher of SAHSYSU, Grant No. ZSQYRSSFAR0004 (to B.X.). The funders had no role in the design andconduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of themanuscript; or decision to submit the manuscript for publication.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
最新[2023]版：
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
JCR分区：
出版当年[2023]版：
Q1 MULTIDISCIPLINARY SCIENCES
最新[2023]版：
Q1 MULTIDISCIPLINARY SCIENCES

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Department of Epidemiology and Biostatistics, Clinical Big Data Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China. [2]Chinese Health RIsk MAnagement Collaboration (CHRIMAC), Shenzhen, Guangdong, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Epidemiology and Biostatistics, Clinical Big Data Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China. [2]Chinese Health RIsk MAnagement Collaboration (CHRIMAC), Shenzhen, Guangdong, China. [8]Guangdong Provincial Key Laboratory of Gastroenterology, Center for Digestive Disease, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China. [15]School of Population and Global Health, Faculty of Medicine, Density and Health Sciences, University of Western Australia, Perth, AU-WA, Australia. [16]Laboratory of Data Discovery for Health (D24H), Hong Kong Science Technology Park, Sha Tin, Hong Kong, China
推荐引用方式(GB/T 7714)：
Xia Bin,He Qiangsheng,Smith Fang Gao,et al.Individualized prevention of proton pump inhibitor related adverse events by risk stratification[J].NATURE COMMUNICATIONS.2024,15(1):3591.doi:10.1038/s41467-024-48007-8.
APA：
Xia Bin,He Qiangsheng,Smith Fang Gao,Gkoutos V Georgios,Nirantharakumar Krishnarajah...&Yuan Jinqiu.(2024).Individualized prevention of proton pump inhibitor related adverse events by risk stratification.NATURE COMMUNICATIONS,15,(1)
MLA：
Xia Bin,et al."Individualized prevention of proton pump inhibitor related adverse events by risk stratification".NATURE COMMUNICATIONS 15..1(2024):3591

资源点击量：43378 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号